Hiltonol® is an established Immuno Oncology and Anti Viral drug product and vaccine adjuvant

Hiltonol®, a synthetic dsRNA viral mimic and host-defense activator, mimics nature by combining the essential elements of human immunity. As an experimental viral mimic and broad activator of innate and adaptive immunity, Hiltonol® has broad biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions. Important mechanisms of action include:

• Hiltonol’s® tumor pro-apoptotic effect induces tumor antigen and neoantigen expression. It promotes induction of natural killer cells and dsRNA dependent systems (OAS, PKR)
.

• Hiltonol® is the preferred critical “danger signal” or immune adjuvant for cancer vaccines. Mechanisms include TLR3 and MDA5 mediated systems.

• Hiltonol® induces killer-cell targeting (chemotaxis) and tumor vascular endothelial infiltration
.

• Hiltonol® supports the hosts ability to overcome immune suppression “checkpoints” in the tumor microenvironment. Via CD8 boost with aPD-1 and APD l-1 checkpoint blockers.

• Hiltonol® activates immunological memory, facilitating durable tumor responses.